You are here
Yves Lussier, MD
Dr. Yves Lussier is an internationally renowned physician-scientist and a pioneer of the field of translational bioinformatics, as attested by his inducted fellowship to the American College of Medical Informatics (2005), his co-founding of two major international conferences (AMIA Summit on Translational Bioinformatics; Translational Bioinformatics Conference held in Qingdao 10/2014), his serving as chairman of the review committee from the National Institute of Health (NIH)/ National Library of Medicine, the invited scientific reporting of the best bioinformatics conference in the journal Genome Biology (ISCB/ISMB; since 2012), his editorial and scientific board memberships (NIH/NLM/BLIRC, NIH/NIGMS, NIH/CSR, NASA/MITAC, College of American Pathologists/SNOMED, JAMIA, WIN Consortium on personalized cancer medicine, IPSEN pharmaceutical, Mouse Genome Database, JBI, BMC Bioinformatics, CERNER), 14 prestigious conference keynotes, 16 outstanding publication awards, and the media reports by New York Times (2008) and Wall Street Journal (2010). Further, Dr. Lussier has published more than 140 articles (>90 publications since 2009), of which >130 appeared in peer-reviewed journals (e.g. Science Translational Medicine, Genome Biology, PLoS Genetics, PLoS Computational Biology, Blood, AJRCCM, JAMIA, Bionformatics, etc.).
Dr. Lussier has mentored 35 graduates and postgraduate students and 11 junior Faculty members. He haa established long-term collaborations with senior scientific leaders of State Key Laboratories in Chongqing, Shanghai, and Nanjing, which will further facilitate staffing and training new teams in China.
While computers understand “mathematical operations” on numerical data, they lack in manipulating qualitative biological and medical data that implicitly contain similarities and relationships - yet cannot be explicitly “added, subtracted, multiplied or divided." Dr. Lussier has devoted his career to solving these problems by bridging the gap between the computational modeling of these networks, clinical medicine, and genomic biology. Thus, for the last twenty years, Dr. Lussier's teams’ discoveries have enabled and accelerated the computed processing of the languages of medicine and biology. Specifically, they have pioneered methods for the formal processing of biomedical concepts (1992-1998), and their modeling in networks for high-throughput multi-class organization, synthesis (1999-2001), similarity integration (2001-3), as well as multi-scale analyses across heterogeneous datasets ranging from genomic science to clinical records (2003-present). Dr. Lussier's teams have pioneered and translated to clinical practice the following discoveries: 1) the first network-anchored terminology in microcomputer-based electronic medical record (65,000 clinical terms; Purkinje.com), 2) the largest nomeclature of signs and symptoms (Systematized Nomenclature of Medicine/SNOMED; 25,000 terms), 3) BioMEdLEE the first natural language processing of biomolecular phenotypes (Patent), 4) the first ontology-anchored clinical event monitor (VIGILENS, in operations in the New York Presbyterian Hospital of Columbia University; in operation since 2002; 40000 lab results tmonitored daily, 500 life-threatening alerts/day, 3 IBM awards), 5) the first and largest panmicrobial expression array (2004), 6) computer-predicted treatment validated in biologic models and a multicenter clinical trial.
Dr. Lussier currently serves as Associate Vice President for Health Sciences and Associate Director for Cancer Informatics and Precision Health for the Cancer Center and the BIO5 Institute of the University of Arizona. He has previously served as Director of three NIH-Funded bioinformatics cores at Columbia University and the University of Chicago. He intends to extend his contribution to China.